Sofamor and Xomed form ENT (ear, nose and throat) distribution deal:
This article was originally published in Clinica
Xomed is to have exclusive, worldwide distribution rights to an ENT image-guided surgery system developed by Sofamor Danek. The product, which will be marketed as the Xomed ENT image-guided system, provides 3D images in real-time. The product will be compatible with Xomed's StraightShot powered tissue resection system. Memphis, Tennessee-based Sofamor will carry out development and manufacturing of the product, while Xomed, of Jacksonville, Florida, will sell through its 89-strong direct sales force and over 100 international distributors.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.